Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6ZMU5
UPID:
TRI72_HUMAN
Alternative names:
Mitsugumin-53
Alternative UPACC:
Q6ZMU5; Q8N4X6; Q8NBD9
Background:
Tripartite motif-containing protein 72, also known as Mitsugumin-53, plays a pivotal role in cellular repair mechanisms. It specifically binds to phosphatidylserine and acts as an oxidation sensor, facilitating the assembly of repair machinery at injury sites. This protein is essential for the nucleation and recruitment of TRIM72-containing vesicles, leading to membrane patch formation. It also plays a role in the transport of DYSF to injury sites and regulates membrane budding and exocytosis.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 72 could open doors to potential therapeutic strategies.